Topas Therapeutics GmbH (Topas), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately.
Paul Sekhri joins Topas Therapeutics as Chairman of the Board
Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer
Crescendo Biologics Ltd (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces that Dr Philip Bland-Ward has been appointed Chief Scientific Officer (CSO). The appointment will take effect in May 2017.
With over 20 years’ experience in the biopharmaceuticals industry, Phil has played a key role in the development of novel antibody therapeutics in multiple disease areas. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme. Phil previously held senior positions at Cambridge Antibody Technology and PanGenetics, and was CSO at Navion, as well as a co-founder of Nascient.
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies
Arsanis, Inc., a clinical- stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post- infection treatment of serious infectious diseases, and Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced today they have entered into an agreement under which Arsanis has secured the exclusive, worldwide license to antibodies targeting respiratory syncytial virus (RSV) that were discovered by Adimab. Arsanis will initially focus on the selection of a lead RSV antibody candidate and has received a grant of up to $9.3 million from the Bill & Melinda Gates Foundation to advance the selected antibody to IND filing.